

Alpha IRB Acquired by Sabai Global, a Portfolio Company of Thompson Street Capital, to Expand IRB Capabilities



Recent trends in the healthcare industry have significantly impacted the need for Institutional Review Boards (IRBs). The increasing complexity and scale of research studies, coupled with the ethical challenges posed by emerging technologies, have amplified the importance of robust ethical oversight. The proliferation of big data analytics, precision medicine, and genetic research has expanded the scope of healthcare research, necessitating careful IRB review to safeguard participant rights and privacy. The emphasis on patient-centered care and shared decision-making has heightened the need for IRBs to ensure that research aligns with patient preferences and values. Additionally, the globalization of research collaborations and the involvement of vulnerable populations have underscored the crucial role of IRBs in maintaining ethical standards across diverse settings and protecting the rights and well-being of research participants.

Founded in 2007, Alpha IRB is a highly regarded organization with a mission to protect the rights and welfare of human research subjects without compromise while delivering premium customer service. Their white-glove service and integrity are well known in the industry, establishing Alpha IRB as a trusted entity. The organization's well-established customer base and exceptional reputation made it an attractive acquisition for Sabai Global.

Leveraging our experience in the pharma services industry and deep understanding of Alpha IRB's unique value proposition, played a pivotal role in advising Alpha IRB. With our guidance, Alpha IRB identified Sabai Global as the ideal transaction partner. This strategic partnership enhances Sabai Global's IRB service offerings and enables them to expand their geographic footprint. The collaboration between Alpha IRB and Sabai Global is poised to bring about further advancements in the IRB services space, benefiting both organizations and the pharma development industry as a whole.

Crosstree helps clients by leveraging deep market expertise to identify the ideal partner that will maximize synergies and position the client to maximize its value.

ABOUT ALPHA IRB



Alpha IRB, founded in 2007, is an organization committed to safeguarding the rights and well-being of human research subjects, without making any concessions. With an unwavering focus on delivering exceptional customer service, Alpha IRB prioritizes the welfare of individuals and values its clientele. Drawing upon their extensive expertise, the team at Alpha IRB has established service standards that instill peace of mind in customers, knowing that their dedicated staff is diligently working to fulfill their needs.

ABOUT SABAI GLOBAL



Headquartered in Wildwood, MO, Sabai Global is a clinical research safety firm specializing in custom solutions for biosafety and human research protections. The Company offers IBC and IRB review and comprehensive biosafety consulting services for sponsors, CROs, and institutions through its subsidiaries Clinical Biosafety Services, Castle IRB, and Shield Consulting.

Sabai Global is a portfolio company of Thompson Street Capital.

CROSSTREE'S EXPERTS ARE SPECIALISTS IN THE NUANCES OF HEALTH SCIENCE AND PROVIDE:

- Deep analytics of capabilities and gaps
- Systemized tactical strategies and a road map to success
- Engaged experts in market analysis, financials, and premium valuations
- Targeted and qualified prospects
- Up-to-date industry trend analysis and forecasting

All while prioritizing corporate core values.

MEETING THE NEEDS OF BOTH THE BUYER AND THE SELLER - BY THE NUMBERS AND BEYOND - IS CROSSTREE'S SPECIALTY.

Crosstree's **proven track record** of superior outcomes is the result of balanced, hands-on guidance from start to close. Partner with the leading health science experts today.



JASON LAYTON

Director

jason.layton@crosstreecapital.com

813-578-7109